Here are the DEF 14A proxy statements from Tvardi Therapeutics, Inc. (TVRD) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow TVRD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TVRD filings page.
Tvardi Therapeutics, Inc. has issued its proxy materials for the 2026 virtual annual meeting of stockholders, to be held on June 9, 2026 at 12:00 p.m. Eastern via webcast. Holders of 9,381,344 shares of common stock outstanding as of April 14, 2026 are entitled to vote.
Stockholders will vote on electing three Class II directors to terms ending in 2029, a non-binding advisory “say-on-pay” vote on executive compensation, an advisory vote on how often to hold future say-on-pay votes, and ratification of the independent registered public accounting firm.
The proxy describes Tvardi’s 2025 reverse merger with Cara Therapeutics, a 1‑for‑3 reverse stock split, an increase in authorized common shares to 150,000,000, and Nasdaq listing under the symbol TVRD. It outlines board independence, committee structure, director pay, 2025 executive pay, annual bonus targets, new stock option grants, and a severance and change-in-control plan covering senior executives.